Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy

Davendra P S Sohal, R. Matthew Walsh, Ramesk K Ramanathan, Alok A. Khorana

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease. Autopsy series reveal that 70% to 85% of patients die of systemic recurrence, rather than local disease, after pancreatic cancer resection. Preclinical studies using genomics and mouse models reveal evidence of metastatic spread even before histopathologic evidence of a pancreatic tumor. Analogous to breast cancer, we propose that the Halstedian approach of treating pancreatic cancer as a local, surgical problem should be replaced by Fisher's alternative hypothesis of cancer as a systemic disease. Newer multiagent chemotherapy regimens have shown meaningful response rates and improvement in overall survival in the metastatic setting and, for the first time, offer investigators an opportunity to use effective systemic therapy. We emphasize that a surgeryfirst approach is not resonant with our current understanding of pancreatic adenocarcinoma biology and that an upfront systemic approach for even resectable pancreatic cancer warrants testing in clinical trials.

Original languageEnglish (US)
Article numberdju011
JournalJournal of the National Cancer Institute
Volume106
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
gemcitabine
Survival
Therapeutics
Genomics
Autopsy
Neoplasms
Research Personnel
Clinical Trials
Breast Neoplasms
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pancreatic adenocarcinoma : Treating a systemic disease with systemic therapy. / Sohal, Davendra P S; Walsh, R. Matthew; Ramanathan, Ramesk K; Khorana, Alok A.

In: Journal of the National Cancer Institute, Vol. 106, No. 3, dju011, 2014.

Research output: Contribution to journalReview article

@article{3273ae50d4874b15a6be73e9893df9be,
title = "Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy",
abstract = "Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease. Autopsy series reveal that 70{\%} to 85{\%} of patients die of systemic recurrence, rather than local disease, after pancreatic cancer resection. Preclinical studies using genomics and mouse models reveal evidence of metastatic spread even before histopathologic evidence of a pancreatic tumor. Analogous to breast cancer, we propose that the Halstedian approach of treating pancreatic cancer as a local, surgical problem should be replaced by Fisher's alternative hypothesis of cancer as a systemic disease. Newer multiagent chemotherapy regimens have shown meaningful response rates and improvement in overall survival in the metastatic setting and, for the first time, offer investigators an opportunity to use effective systemic therapy. We emphasize that a surgeryfirst approach is not resonant with our current understanding of pancreatic adenocarcinoma biology and that an upfront systemic approach for even resectable pancreatic cancer warrants testing in clinical trials.",
author = "Sohal, {Davendra P S} and Walsh, {R. Matthew} and Ramanathan, {Ramesk K} and Khorana, {Alok A.}",
year = "2014",
doi = "10.1093/jnci/dju011",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Pancreatic adenocarcinoma

T2 - Treating a systemic disease with systemic therapy

AU - Sohal, Davendra P S

AU - Walsh, R. Matthew

AU - Ramanathan, Ramesk K

AU - Khorana, Alok A.

PY - 2014

Y1 - 2014

N2 - Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease. Autopsy series reveal that 70% to 85% of patients die of systemic recurrence, rather than local disease, after pancreatic cancer resection. Preclinical studies using genomics and mouse models reveal evidence of metastatic spread even before histopathologic evidence of a pancreatic tumor. Analogous to breast cancer, we propose that the Halstedian approach of treating pancreatic cancer as a local, surgical problem should be replaced by Fisher's alternative hypothesis of cancer as a systemic disease. Newer multiagent chemotherapy regimens have shown meaningful response rates and improvement in overall survival in the metastatic setting and, for the first time, offer investigators an opportunity to use effective systemic therapy. We emphasize that a surgeryfirst approach is not resonant with our current understanding of pancreatic adenocarcinoma biology and that an upfront systemic approach for even resectable pancreatic cancer warrants testing in clinical trials.

AB - Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease. Autopsy series reveal that 70% to 85% of patients die of systemic recurrence, rather than local disease, after pancreatic cancer resection. Preclinical studies using genomics and mouse models reveal evidence of metastatic spread even before histopathologic evidence of a pancreatic tumor. Analogous to breast cancer, we propose that the Halstedian approach of treating pancreatic cancer as a local, surgical problem should be replaced by Fisher's alternative hypothesis of cancer as a systemic disease. Newer multiagent chemotherapy regimens have shown meaningful response rates and improvement in overall survival in the metastatic setting and, for the first time, offer investigators an opportunity to use effective systemic therapy. We emphasize that a surgeryfirst approach is not resonant with our current understanding of pancreatic adenocarcinoma biology and that an upfront systemic approach for even resectable pancreatic cancer warrants testing in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84898731031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898731031&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju011

DO - 10.1093/jnci/dju011

M3 - Review article

C2 - 24563516

AN - SCOPUS:84898731031

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

M1 - dju011

ER -